Sign up online today & collaborate
or click here to find out more
AstraZeneca has sold Tillotts Pharma rights to gastroenterology drug Entocort for $215 million, under a bid to hone its focus on core areas such as cancer and diabetes.
Tillotts Pharma, a Swiss-based subsidiary of Japanese group Zeria, is picking up global rights (excluding the US) to the drug, which is marketed for Crohn's disease and ulcerative colitis.
For more click here